山东大学学报 (医学版) ›› 2021, Vol. 59 ›› Issue (7): 1-9.doi: 10.6040/j.issn.1671-7554.0.2021.0055
• 基础医学 •
褚晏1,2,刘端瑞1,2,朱文帅1,2,樊荣1,2,马晓丽1,汪运山1,郏雁飞1
CHU Yan1,2, LIU Duanrui1,2, ZHU Wenshuai1,2, FAN Rong1,2, MA Xiaoli1, WANG Yunshan1, JIA Yanfei1
摘要: 目的 探讨胃癌中DNA甲基化转移酶(DNMT1、DNMT3A、DNMT3B)表达的临床意义与预后的相关性。 方法 运用TCGA和GEO数据库分析DNA甲基化转移酶在胃癌和正常组织中的表达差异; 运用生存期分析软件Kaplan-Meier plotter分析DNA甲基化转移酶对胃癌患者预后的影响;下载TCGA和GEO数据库中的原始数据,分析DNA甲基化转移酶与临床病理参数之间的关系;采用基因富集分析(GSEA)结合蛋白互作网络进行DNMT3B的生物学功能研究。TCGA数据库分析DNMT3B升高促进胃癌进展的具体机制。 结果 在胃癌组织中3种DNA甲基化转移酶的表达均高于癌旁正常组织;生存分析结果发现,DNMT3A、DNMT3B高表达的患者总生存期较短;DNMT3B表达与组织学分型相关,在肠型胃癌中表达较高;幽门螺旋杆菌感染可促进DNMT3B表达;DNMT3B可能通过影响BUB1、HDAC2的甲基化促进胃癌的进展。 结论 DNA甲基化转移酶在胃癌组织中高表达,DNMT3B是胃癌患者的一个预后指标,可能成为临床诊治胃癌的生物标志物。
中图分类号:
[1] Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention[J]. Cancer Epidemiol Biomarkers Prev, 2014, 23(5): 700-713. [2] 王攀, 赵洪林, 任凡, 等. 表观遗传学在恶性肿瘤发生发展和治疗中的新进展[J]. 中国肺癌杂志, 2020, 23(2): 91-100. WANG Pan, ZHAO Honglin, REN Fan, et al. New progress of epigenetics in the occurrence, development and treatment of malignant tumors [J]. Chinese Journal of Lung Cancer, 2020, 23(2): 91-100. [3] 杨梦迪, 王学红, 张梅. 表观遗传学在胃癌中的研究进展[J]. 癌症进展, 2019, 17(5): 503-506. YANG Mengdi, WANG Xuehong, ZHANG Mei. Research progress of epigenetics in gastric cancer [J]. Cancer Progress, 2019, 17(5): 503-506. [4] 赵琦, 相绿竹, 彭瑞, 等. DNA及RNA甲基化检测在肿瘤诊断中的研究进展[J]. 国际检验医学杂志, 2019, 40(11): 1356-1360. ZHAO Qi, XIANG Lüzhu, PENG Rui, et al. Research progress of DNA and RNA methylation detection in tumor diagnosis [J]. International Journal of Laboratory Medicine, 2019, 40(11): 1356-1360. [5] 肖枭, 王艳林, 黄利鸣. DNA甲基转移酶与肿瘤关系的研究进展[J]. 生命科学, 2019, 31(1): 87-92. XIAO Xiao, WANG Yanlin, HUANG Liming. Research progress on the relationship between DNA methyltransferase and tumor [J]. Life Sciences, 2019, 31(1): 87-92. [6] Giri AK, Aittokallio T. DNMT inhibitors increase methylation in the cancer genome [J]. Front Pharmacol, 2019, 10: 385. doi: 10.3389/fphar.2019.00385. [7] Cristina S, José-Enériz ES, Maravilla EM, et al. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression [J]. Nat Med, 2019, 25(7): 1073-1081. [8] 李含含, 段圆圆, 刘美君, 等. miR-142靶向DNMT1抑制乳腺癌细胞的迁移[J]. 生物技术, 2020, 30(1): 75-81. LI Hanhan, DUAN Yuanyuan, LIU Meijun, et al. miR-142 targeting DNMT1 inhibits the migration of breast cancer cells [J]. Biotechnology, 2020, 30(1): 75-81. [9] Li SX, Han ZP, Zhao NP, et al. Inhibition of DNMT suppresses the stemness of colorectal cancer cells through down-regulating Wnt signaling pathway [J]. Cell Signal, 2018, 47: 79-87. doi: 10.1016/j.cellsig.2018.03.014. [10] Wang LH, Huang J, Wu CR, et al. Downregulation of miR-29b targets DNMT3b to suppress cellular apoptosis and enhance proliferation in pancreatic cancer [J]. Mol Med Rep, 2018, 17(2): 2113-2120. [11] 王震凯, 杨晓倩, 叶雅沁, 等. DNA甲基转移酶在胃癌中的表达及其意义[J]. 胃肠病学, 2019, 24(2): 81-85. WANG Zhenkai, YANG Xiaoqian, YE Yaqin, et al. Expression and significance of DNA methyltransferase in gastric cancer [J]. Gastroenterology, 2019, 24(2): 81-85. [12] Wu S, Xie J, Shi H, et al. miR-492 promotes chemoresistance to CDDP and metastasis by targeting inhibiting DNMT3B and induces stemness in gastric cancer [J]. Biosci Rep, 2020, 40(3): BSR20194342. doi: 10.1042/BSR20194342. [13] 殷科, 盛贤能, 郭宇, 等. DNMT1、DNMT3B在胃癌中的表达及其临床意义[J].现代实用医学, 2013, 25(12): 1386-1388. YIN Ke, SHENG Xianneng, GUO Yu, et al. Expression and clinical significance of DNMT1、DNMT3Bin gastric cancer [J]. Modern Practical Medicine, 2013, 25(12): 1386-1388. [14] Venerito M, Alexander L, Rokkas T, et al. Gastric cancer-clinical and epidemiological aspects [J]. Helicobacter, 2016, 21(Suppl 1): 39-44. [15] Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors [J]. J Surg Oncol, 2013, 107(3): 230-236. [16] 王永云, 靳文, 俞兰. 胃癌相关基因及靶向治疗的研究进展[J]. 医学综述, 2020, 26(19): 3814-3819. WANG Yongyun, JIN Wen, YU Lan. Research progress of gastric cancer related genes and targeted therapy[J]. Medical Review, 2020, 26(19): 3814-3819. [17] 纪艺珍,张瑞晴,张佳荣. DNA甲基化在女性正常妊娠与输卵管妊娠中的作用[J]. 检验医学与临床, 2017, 14(17): 2643-2645. JI Yizhen, ZHANG Ruiqing, ZHANG Jiarong. The role of DNA methylation in female normal pregnancy and tubal pregnancy [J]. Laboratory Medicine and Clinical, 2017, 14(17): 2643-2645. [18] Moore LD, Le T, Fan G. DNA methylation and its basic function [J]. Neuropsychopharmacology, 2013, 38(1): 23-38. [19] Frank Lyko. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation [J]. Nat Rev Genet, 2018, 19(2): 81-92. [20] Zhang ZM, Lu R, Wang P, et al. Structural basis for DNMT3A-mediated de novo DNA methylation [J]. Nature, 2018, 554(7692): 387-391. [21] Tajima S, Suetake I, Takeshita K, et al. Domain structure of the DNMT1, DNMT3A, and DNMT3B DNA methyltransferases [J]. Adv Exp Med Biol, 2016, 945: 63-86. doi: 10.1007/978-3-319-43624-1_4. [22] Cao XY, Ma HX, Shang YH, et al. DNA methyltransferase3a expression is an independent poor prognostic indicator in gastric cancer [J]. World J Gastroenterol, 2014, 20(25): 8201-8208. [23] 李小燕,何杰,余觅,等 BUB1基因在胃癌组织中高表达:基于Oncomine数据库及生物信息学方法[J].南方医科大学学报,2020,40(5):683-692. LI Xiaoyan, HE Jie, YU Mi, et al. BUB1 gene is highlyexpressed in gastric cancer:analysis based on Oncominedatabase and bioinformatics[J]. Journal of Southern Medical University, 2020, 40(5): 683-692. [24] Zhu LJ, Pan Y, Chen XY, et al. BUB1 promotes proliferation of liver cancer cells by activating SMAD2 phosphorylation [J]. Oncol Lett, 2020, 19(5): 3506-3512. [25] Feng H, Gu ZY, Li Q, et al. Identification of significant genes with poor prognosis in ovarian cancer via bioinformatical analysis [J]. J Ovarian Res, 2019, 12(1): 35. [26] Tang W, Zhou W, Xiang L, et al. The p300/YY1/miR-500a-5p/HDAC2 signalling axis regulates cell proliferation in human colorectal cancer [J]. Nat Commun, 2019, 10(1): 663. [27] 王玉芝. TRPS1调控HDAC2在乳腺癌中的作用和机制研究[D]. 南京: 东南大学, 2018. [28] Qi ZP, Yalikong A, Zhang JW, et al. HDAC2 promotes the EMT of colorectal cancer cells and via the modular scaffold function of ENSG00000274093.1 [J]. J Cell Mol Med, 2021, 25(2): 1190-1197. [29] Zhou Z, Li HQ, Liu F. DNA Methyltransferase Inhibitors and their Therapeutic Potential [J]. Curr Top Med Chem, 2018, 18(28): 2448-2457. [30] Da Costa EM, McInnes G, Beaudry A, et al. DNA Methylation-Targeted Drugs [J]. Cancer J, 2017, 23(5): 270-276. |
[1] | 米琦,史爽,李娟,李培龙,杜鲁涛,王传新. 膀胱癌circRNAs介导的ceRNA网络及预后评估模型的构建[J]. 山东大学学报 (医学版), 2021, 59(6): 94-102. |
[2] | 罗兵. EB病毒对胃癌表观遗传学的影响[J]. 山东大学学报 (医学版), 2021, 59(5): 30-39. |
[3] | 耿晨,杨阳,赵月,刘浩冉,晁岚. 子宫腺肌病中差异基因筛选及Wilms tumor-1的表达[J]. 山东大学学报 (医学版), 2021, 59(4): 79-86. |
[4] | 谢同辉,陈志强,常建华,赵丹文,徐博文,智绪亭. 肝内胆管癌根治性切除术后生存因素分析及列线图的建立[J]. 山东大学学报 (医学版), 2021, 59(4): 93-99. |
[5] | 李湘青,殷欣,赵雪莲,赵培庆. NK细胞亚群CD56bright在帕金森患者外周血中的表达及临床意义[J]. 山东大学学报 (医学版), 2021, 59(2): 34-40. |
[6] | 贾明旺,廖广园,熊明媚,徐文婷,王银玲,王懿春. 84例妊娠合并肺高血压患者预后的临床分析[J]. 山东大学学报 (医学版), 2021, 59(1): 34-39. |
[7] | 甄秋来,吕欣然,叶辉,丁绪超,柴小雪,胡辛,周明,曹莉莉. 基于TCGA数据库预测结肠癌预后基因及其临床应用价值[J]. 山东大学学报 (医学版), 2021, 59(1): 64-71. |
[8] | 栗英林,宋道庆,徐忠华. 应用生物信息学方法分析肾透明细胞癌中FKBP11的表达[J]. 山东大学学报 (医学版), 2020, 1(9): 45-51. |
[9] | 路璐,孙志钢,张楠. 继发性嗜血细胞综合征1例[J]. 山东大学学报 (医学版), 2020, 1(7): 122-124. |
[10] | 史爽,李娟,米琦,王允山,杜鲁涛,王传新. 胃癌miRNAs预后风险评分模型的构建与应用[J]. 山东大学学报 (医学版), 2020, 1(7): 47-52. |
[11] | 姚宇,王文军,梁玉灵. 他汀类药物对70例肺栓塞患者预后的影响[J]. 山东大学学报 (医学版), 2020, 58(11): 76-80. |
[12] | 支梦伟,江志伟,戴新娟,王刚,程伟. 加速康复外科指导下胃癌患者围手术期心率变异度的临床观察[J]. 山东大学学报 (医学版), 2020, 58(11): 85-91. |
[13] | 李星凯,刘战业,姜运峰,李军. 原发性中央型和周围型肺鳞癌临床病理学及预后差异[J]. 山东大学学报(医学版), 2017, 55(9): 73-78. |
[14] | 宗帅,肖东杰,刘华,郏雁飞,马晓丽,李焕杰,黎娉,郑燕,汪运山. CSN5在胃癌中的表达及与患者预后的相关性[J]. 山东大学学报(医学版), 2017, 55(7): 12-16. |
[15] | 孙启晶,陈方方,李春晓,张才擎. PNI及HGB评估中晚期非小细胞肺癌患者预后的临床价值[J]. 山东大学学报(医学版), 2017, 55(4): 55-59. |
|